A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- A. Michael Lincoff, MD
The Cleveland Clinic
Principal Investigator - John H Alexander, MD, MHS
Duke Clinical Research Institute
Principal Investigator - Roxana Mehran, MD
Icahn School of Medicine at Mount Sinai
Principal Investigator - Steven L Zelenkofske, DO, FACC
Regado Biosciences
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Black Hills Cardiovascular Research
Rapid City, South Dakota, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Sept 2013
- Primary completion
- 31 Aug 2014
- Completion
- 31 Aug 2014
- Last update posted
- 23 Oct 2014
- Registered enrollment
- 3,232
- Registry id
- NCT01848106
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.